OncoMasTR is a novel prognostic assay for early stage breast cancer that is under development at OncoMark, and due for launch in mid 2018. The biomarker assay will determine the risk of recurrence for early breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients.  

The OncoMasTR qPCR test is performed on 3 genes (+ 3 reference genes) using standard RT qPCR equipment.

On a large set of clinical samples tested to date, the assay yielded:

  • Binary output (low or high risk of recurrence)
  • Highly accurate results that reflect the true recurrence rate, detecting 67% of low risk patients with a 3% recurrence within this cohort of low risk patients [1}.

The patient benefits of OncoMasTR will be that it will help the clinician to determine an optimal treatment plan for their patients, reduce healthcare costs, avoid unnecessary chemotherapy for the patient and ultimately improve quality of life. 



The benefits of the OncoMasTR assay:

Improved diagnostic performance – The OncoMasTR assay will provide better performance in terms of prognostic determination than other tests currently available and will provide a binary output for decision making (i.e. there will be no intermediate group.)  A binary output is the preferred output format for clinicians and is more clinically useful.

Advantageous / Favourable Format – The assay will be available in a kit-based format suitable for use in hospital laboratories, eliminating the need to transfer clinical materials off-site as with competitor assays.

Fits into Workflow – The OncoMasTR assay is performed using standard qRT-PCR procedures and equipment. qRT-PCR is a routine diagnostic technology, with systems commonly available in hospital laboratories.

Cost-effectiveness – The OncoMasTR assay will be significantly less expensive than the market leaders Oncotype DX and Mammaprint and as the assay will be performed on standard lab equipment, users will not need upfront capital investment.

Additionally, the OncoMasTR assay provides:

  • Coverage of lymph node positive breast cancer
  • Incorporation of standard clinic-pathological factors
  • Reduced complexity – 3 genes (plus 3 reference genes) are all that’s required for this assay

[1] Lanigan F et al. FEBS J., 2015; 282(18), 3455-3473